Jan Vesterbacka

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CELL HOST & MICROBE. 2024;32(2):156-161.e3

Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant

Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: LIVER INTERNATIONAL. 2024;44(1):228-240

The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years

Kamal H; Lindahl K; Ingre M; Gahrton C; Karkkonen K; Nowak P; Vesterbacka J; Stal P; Wedemeyer H; Duberg A-S; Aleman S
Article: NPJ BIOFILMS AND MICROBIOMES. 2023;9(1):104

Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV

Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren H-G; Buggert M; Manoharan L; Chen MS; Aleman S; Sonnerborg A; Nowak P
Article: EBIOMEDICINE. 2023;94:104700

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452

Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: AIDS. 2023;37(7):1023-1033

Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment

Svensson Akusjarvi S; Krishnan S; Ambikan AT; Mikaeloff F; Munusamy Ponnan S; Vesterbacka J; Lourda M; Nowak P; Sonnerborg A; Neogi U
Article: PLOS ONE. 2023;18(12):e0295838

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: IMMUNITY. 2022;55(9):1732-1746.e5

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination

Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: LIFE SCIENCE ALLIANCE. 2022;5(9):e202201405

Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection

Ambikan AT; Svensson-Akusjarvi S; Krishnan S; Sperk M; Nowak P; Vesterbacka J; Sonnerborg A; Benfeitas R; Neogi U
Article: HIV MEDICINE. 2022;23(8):895-910

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Anne AV; Oellinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K
Article: MOLECULAR MEDICINE. 2022;28(1):54

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine

Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Ballesteros OR; Muvva JR; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren H-G; Aleman S; Sandberg JK
Article: COMMUNICATIONS BIOLOGY. 2022;5(1):357

Peripheral blood CD4⁺CCR6⁺ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals

Svensson Akusjarvi S; Krishnan S; Jutte BB; Ambikan AT; Gupta S; Rodriguez JE; Vegvari A; Sperk M; Nowak P; Vesterbacka J; Svensson JP; Sonnerborg A; Neogi U
Article: ISCIENCE. 2022;25(1):103607

Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling

Akusjarvi SS; Ambikan AT; Krishnan S; Gupta S; Sperk M; Vegvari A; Mikaeloff F; Healy K; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: EBIOMEDICINE. 2021;74:103705

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: LANCET HIV. 2021;8(11):e711-e722

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

Bansi-Matharu L; Phillips A; Oprea C; Grabmeier-Pfistershammer K; Gunthard HF; De Wit S; Guaraldi G; Vehreschild JJ; Wit F; Law M; Wasmuth J-C; Chkhartishvili N; Monforte AD; Fontas E; Vesterbacka J; Miro JM; Castagna A; Stephan C; Llibre JM; Neesgaard B; Greenberg L; Smith C; Kirk O; Duvivier C; Dragovic G; Lundgren J; Dedes N; Knudsen A; Gallant J; Vannappagari V; Peters L; Elbirt D; Sarcletti M; Braun DL; Necsoi C; Mussini C; Muccini C; Bolokadze N; Hoy J; Mocroft A; Ryom L
Article: JOURNAL OF VIROLOGY. 2021;95(18):e0047921-10.1128/jvi.00421

Fecal Metabolome Signature in the HIV-1 Elite Control Phenotype: Enrichment of Dipeptides Acts as an HIV-1 Antagonist but a Prevotella Agonist

Sperk M; Ambikan AT; Ray S; Singh K; Mikaeloff F; Diez RC; Narayanan A; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: LAKARTIDNINGEN. 2021;118:21047

Tocilizumab bör övervägas i tidigt skede av svår covid-19.

Blennow O; Vesterbacka J; Nowak P
Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159

Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication

Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjarvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlen G; Asghar M; Sallberg M; Vesterbacka J; Nowak P; Vegvari A; Sonnerborg A; Treutiger CJ; Neogi U
Article: LAKARTIDNINGEN. 2020;117:20115

Tidiga erfarenheter av steroidbehandling vid covid-19.

Kan B; Ahl M; Blennow O; Eriksson P; Nowak P; Parke Å; Stojanovic B; Tovatt T; Vesterbacka J
Article: MEDICINE. 2018;97(12):e0162

Nonopportunistic infection leading to rapidly progressive dementia in a patient with HIV/AIDS A case report

Eimer J; Vesterbacka J; Savitcheva I; Press R; Roshanisefat H; Nowak P
Article: SCIENTIFIC REPORTS. 2017;7(1):6269

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers

Vesterbacka J; Rivera J; Noyan K; Parera M; Neogi U; Calle M; Paredes R; Sonnerborg A; Noguera-Julian M; Nowak P
Article: INFECTIOUS DISEASES. 2016;48(6):449-452

Transition of HIV-infected youths from paediatric to adult care, a Swedish single-centre experience

Westling K; Naver L; Vesterbacka J; Belfrage E
Article: AIDS. 2015;29(18):2409-2418

Gut microbiota diversity predicts immune status in HIV-1 infection

Nowak P; Troseid M; Avershina E; Barqasho B; Neogi U; Holm K; Hov JR; Noyan K; Vesterbacka J; Svard J; Rudi K; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2015;31(8):830-836

Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy

Vesterbacka J; Barqasho B; Haggblom A; Nowak P
Article: LAKARTIDNINGEN. 2014;111(22-23):1002-1003

[From pediatric to adult clinic through a transition clinic. Experiences of HIV-infected young people who have been ill all their lives].

Westling K; Belfrage E; Navér L; Vesterbacka J
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(7):543-551

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

Andersson L-M; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sonnerborg A; Gisslen M
Article: PLOS ONE. 2013;8(1):e55038

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy

Vesterbacka J; Nowak P; Barqasho B; Abdurahman S; Nystrom J; Nilsson S; Funaoka H; Kanda T; Andersson L-M; Gisslen M; Sonnerborg A
Article: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2011;38(6):727-742

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients

Roshammar D; Simonsson USH; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslen M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(4):349-357

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na⟨ve HIV-1 infected patients

Josephson F; Andersson MCH; Flamholc L; Gisslen M; Hagberg L; Ormaasen V; Sonnerborg A; Vesterbacka J; Bottiger Y
Article: AIR MEDICAL JOURNAL. 2001;20(3):28-31

A rural ambulance helicopter system in northern Sweden.

Vesterbacka J; Eriksson A
Visa fler

Alla övriga publikationer

Review: AIDS REVIEWS. 2024;26(1):41-47

HTLV in Sweden.

Vesterbacka J; Svensson A-K; Nowak P
Letter: CLINICAL INFECTIOUS DISEASES. 2023;76(10):1864-1865

Successful Combination Treatment for Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Blennow O; Vesterbacka J; Tovatt T; Nowak P
Letter: JOURNAL OF INTERNAL MEDICINE. 2022;292(1):168-171

Incidence and severity of COVID-19 in adults with and without HIV diagnosis

Hedberg P; Vesterbacka J; Blennow O; Missailidis C; Nowak P; Naucler P
Letter: AIDS. 2022;36(3):479-481

High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?

Xu X; Vesterbacka J; Aleman S; Nowak P
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;289(3):434-436

Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study

Eimer J; Vesterbacka J; Svensson A-K; Stojanovic B; Wagrell C; Sonnerborg A; Nowak P
Thesis / dissertation: 2017

The role of microbial translocation and gut microbiota in HIV-1 infection

Vesterbacka, Jan

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2017

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI